109 related articles for article (PubMed ID: 20956951)
1. Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation.
Medd P; Littlewood S; Danby R; Malladi R; Clifford R; Wareham D; Jeffery K; Ferry B; Roberts D; Peniket A; Littlewood T
Bone Marrow Transplant; 2011 Jul; 46(7):993-9. PubMed ID: 20956951
[TBL] [Abstract][Full Text] [Related]
2. Correlation between paraproteinaemia and viral reactivation after allo-SCT.
Metafuni E; Giammarco S; Bellesi S; Chiusolo P; Laurenti L; Sorà F; Cattani P; Santangelo R; Manzara S; Leone G; Sica S
Bone Marrow Transplant; 2012 Sep; 47(9):1262; author reply 1263. PubMed ID: 22327136
[No Abstract] [Full Text] [Related]
3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
4. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
Satwani P; Baldinger L; Freedman J; Jacobson JS; Guerra J; van de Ven C; Morris E; Garvin J; George D; Bradley MB; Bhatia M; Tallamy B; Schwartz J; Jin Z; Cairo MS
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083
[TBL] [Abstract][Full Text] [Related]
6. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Yang DH; Lee JJ; Kim YK; Kim HJ; Shin HJ; Chung JS; Cho GJ
Am J Hematol; 2008 Aug; 83(8):649-53. PubMed ID: 18528826
[TBL] [Abstract][Full Text] [Related]
7. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
[TBL] [Abstract][Full Text] [Related]
8. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
George B; Kerridge I; Gilroy N; Huang G; Hertzberg M; Gottlieb D; Bradstock K
Bone Marrow Transplant; 2010 May; 45(5):849-55. PubMed ID: 19915635
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
Lamba R; Carrum G; Myers GD; Bollard CM; Krance RA; Heslop HE; Brenner MK; Popat U
Bone Marrow Transplant; 2005 Nov; 36(9):797-802. PubMed ID: 16151431
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
[TBL] [Abstract][Full Text] [Related]
12. Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival.
Lim ZY; Ingram W; Brand R; Akthari M; Milojkovic D; Ho AY; Devereux S; Pagliuca A; Duarte RF; Mufti GJ
Bone Marrow Transplant; 2007 Oct; 40(8):747-52. PubMed ID: 17704796
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.
Malladi RK; Peniket AJ; Littlewood TJ; Towlson KE; Pearce R; Yin J; Cavenagh JD; Craddock C; Orchard KH; Olavarria E; McQuaker G; Collin M; Marks DI;
Bone Marrow Transplant; 2009 May; 43(9):709-15. PubMed ID: 19029965
[TBL] [Abstract][Full Text] [Related]
14. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab.
Song WK; Min YH; Kim YR; Lee SC
Ophthalmology; 2008 Oct; 115(10):1766-70. PubMed ID: 18562004
[TBL] [Abstract][Full Text] [Related]
16. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.
Hill QA; Hill A; Collyns TA; Pearce RM; Cook G
Bone Marrow Transplant; 2008 Apr; 41(8):749-51. PubMed ID: 18195685
[No Abstract] [Full Text] [Related]
17. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
Das-Gupta EP; Russell NH; Shaw BE; Pearce RM; Byrne JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):724-33. PubMed ID: 17531783
[TBL] [Abstract][Full Text] [Related]
19. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
[TBL] [Abstract][Full Text] [Related]
20. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Ingram W; Devereux S; Das-Gupta EP; Russell NH; Haynes AP; Byrne JL; Shaw BE; McMillan A; Gonzalez J; Ho A; Mufti GJ; Pagliuca A
Br J Haematol; 2008 Apr; 141(2):235-43. PubMed ID: 18318762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
